Sanofi licenses Sino Biopharm’s transplant drug for $135M upfrontnews2026-03-04T12:05:54+00:00March 4th, 2026|Endpoints News|
UCB boards T cell engager train in $60M upfront deal with Antengenenews2026-03-04T08:51:51+00:00March 4th, 2026|Endpoints News|
Blackstone to support Teva on Sanofi-partnered TL1A with $400Mnews2026-03-04T08:03:51+00:00March 4th, 2026|Endpoints News|
EveryOne Medicines shuts down, ending custom cure venture that banked on new FDA pathwaynews2026-03-03T16:33:03+00:00March 3rd, 2026|Endpoints News|
Esperion to buy Corstasis and its nasal spray for edema for $75M upfrontnews2026-03-03T11:56:39+00:00March 3rd, 2026|Endpoints News|
Candid to go public via reverse merger with Rallybionews2026-03-02T14:28:52+00:00March 2nd, 2026|Endpoints News|
WuXi XDC makes an ADC linker deal with Earendil for up to $885Mnews2026-02-27T16:13:26+00:00February 27th, 2026|Endpoints News|
Novartis closes Avidity deal as rare heart disease spinout launchesnews2026-02-27T14:51:42+00:00February 27th, 2026|Endpoints News|
Protagonist to opt out of Takeda profit-sharing deal, will receive $400M in cashnews2026-02-26T14:58:16+00:00February 26th, 2026|Endpoints News|
OrbiMed jumps to number one on the top 100 list of biotech venture investorsnews2026-02-26T12:00:39+00:00February 26th, 2026|Endpoints News|
